The Budget Impact of Monoclonal Antibodies Used to Treat Metastatic Colorectal Cancer in Minas Gerais, Brazil.
Wânia Cristina da SilvaBrian B GodmanFrancisco de Assis AcurcioMariângela Leal CherchigliaAntony Paul MartinKonrad MaruszczykJans Bastos IzidoroMarcos André PortellaAgner Pereira LanaOrozimbo Henriques Campos NetoEli Iola Gurgel AndradePublished in: Applied health economics and health policy (2021)
These results highlight the appreciable costs for incorporating bevacizumab, cetuximab, and panitumumab into the SUS. Appreciable discounts are likely to be necessary before incorporation of these mAbs is approved.